In a short period of time Transgenomic, Inc. has evolved into a global biotechnology company specializing in high sensitivity genetic variation and mutation analysis. Today, the company took a major step towards prominence with the announcement they will be making a presentation at the American Association for Cancer Research (AACR) meeting in Orlando, Florida on April 2-6 of this year.
The presentation will be based upon completed studies by the company’s scientists. The studies employ the company’s high-sensitivity cancer mutation assays using two proprietary technologies, Ice COLD-PCR and BLOCker.
Katherine Richardson, Ph.D, who serves as the Vice President of Research and Development for Transgenomic, commented on these technologies by stating, “BLOCker-Sequencing and Ice COLD-PCR are breakthrough methodologies that allow Sanger Sequencing platforms to be used to detect and identify mutations at or beyond the levels achieved with allele-specific probes or next generation sequencing platforms.”
Leading the way at Transgenomic is Craig Tuttle who serves as the company’s CEO and President. In reference to these technologies, Tuttle added, “The application of Ice COLD-PCR and BLOCker-Sequencing in the field of oncology represents a key element in our corporate strategy as we deliver on our mission to be the leading provider of products and services in DNA mutation detection and discovery in clinical research, molecular diagnostics and personalized medicine. We are rapidly developing Ice COLD-PCR and BLOCker-Sequencing assays for important cancer genes such as EGFR, K-RAS, PIK3CA, BRAF, NRAS and TP53, and, in fact, most of these assays are already being offered to our pharmaceutical company partners through our Pharmacogenomics services laboratory in support of their clinical trial studies. Our next goal is to offer BLOCker-Sequencing assay kits for laboratories to test tumor tissue directly with a high mutation detection rate and to combine Ice COLD-PCR and BLOCker-Sequencing in kits for testing these same gene mutations in blood where the highest sensitivity is required. We believe that this combination of technologies is unique in the marketplace and will enable us to become a significant contributor in the molecular analysis and detection of cancer.”
To learn more about this news or the company as a whole, visit the company website at: www.transgenomic.com